Sign In
Buy KZIA
$10.95
-0.84 (-7.12%)
At Close: Jun 03, 2026
Kazia Therapeutics receives full regulatory approval for EVT801 phase 1 study
11:11pm, Wednesday, 01'st Sep 2021
Kazia Therapeutics Ltd has received full regulatory approval for its planned phase 1 study for EVT801 from L'Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), the French
Kazia Therapeutics directors support oncology-focused drug strategy with on-market purchases
02:13am, Monday, 30'th Aug 2021
Kazia Therapeutics Ltd directors Dr James Garner and Iain Ross have shown their faith in the company's oncology-focused drug development strategy by acquiring shares on-market. Dr Garner, who is chie
Kazia Therapeutics has 'busy and productive' June quarter with important readouts slated for second half
02:12am, Friday, 30'th Jul 2021
Kazia Therapeutics Ltd has had a “busy and productive” June quarter as it makes great strides with the paxalisib clinical program, including the launch of two new studies. The oncology-focused d
Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day
10:00am, Wednesday, 21'st Jul 2021
SYDNEY, July 21, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading drug development company in the field of brain cancer, today recognizes Glioblastoma (GBM) Awarenes
Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs
10:00am, Wednesday, 30'th Jun 2021
SYDNEY , June 30, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its tw
Kazia Therapeutics makes strong progress with clinical programs for paxalisib and EVT801
02:55am, Wednesday, 30'th Jun 2021
Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) has made strong progress in the first half of 2021 with its oncology-focused drug development program, including the pipeline assets of paxalisib and EVT
Kazia Therapeutics lands key manufacturing patents for paxalisib in US and India
10:24pm, Wednesday, 23'rd Jun 2021
Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) has secured manufacturing patents for its paxalisib cancer treatment candidate in key territories, extending its patent protection out until 2036. The on
SYDNEY, June 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has entered a collaboration with
Kazia Therapeutics to collaborate with Cornell University for new paxalisib phase II clinical trial
10:27pm, Monday, 14'th Jun 2021
Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) has teamed up with a medical college from Cornell University to launch a phase two clinical study investigating Kazia's investigational new drug paxalisi
Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient
08:00am, Monday, 07'th Jun 2021
SYDNEY, June 7, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia's investig
Kazia Therapeutics study of paxalisib in primary CNS Lymphoma at Dana-Farber enrols first patient
10:37pm, Sunday, 06'th Jun 2021
Kazia Therapeutics Ltd's (ASX:KZA) (FRA:NV9M) (NASDAQ:KZIA) phase-II study of paxalisib in Primary CNS Lymphoma has been initiated at Dana-Farber Cancer Institute in Boston, Massachusetts, with the fi
Kazia Therapeutics directors demonstrate confidence in bio-tech strategy with on-market purchases
03:03am, Wednesday, 02'nd Jun 2021
Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) directors have demonstrated confidence in the company's bio-tech strategy with on-market share purchases. Non-executive director Steven Coff
Kazia Therapeutics directors demonstrate confidence in company with on-market purchases
02:51am, Tuesday, 04'th May 2021
Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) directors have demonstrated their confidence in the company's biotech strategy with on-market purchases. Non-executive director Steven Coffey
Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) has kicked off 2021 with a trifecta of March quarter licensing deals, leaving it "a vastly stronger and more substantial business", accordin
Kazia Therapeutics' EVT801 deal secures price target of A$2.60 from Corporate Connect and BUY rating from HC Wainwright
10:43pm, Sunday, 25'th Apr 2021
Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) recently announced an agreement with Evotec SE (FRA:EVT) to in-license the global rights to EVT801, a novel inhibitor of vascular endothelial g
